Pregunta:
Zonisamide pharmacokinetics and adverse effects
Autor: SuzukiRespuesta:
Cross reactivity with other sulfonamides should be reviewed. Its use should be monitored in patients with reported allergies. Zonisamide is approved for use in patients with partial epilepsy. It is metabolized by the CYP3A4 isozyme and may, to a lesser extent, be affected by CYP3A5 and CYP2C19. In addition to typical CNS adverse effects, zonisamide may cause kidney stones. Oligohidrosis has been reported, and patients should be monitored for increased body temperature and decreased sweating.
0 / 5 (0 calificaciones)
1 answer(s) in total